Education
About Us
Working with TipRanks
Follow Us
Evgen Pharma (GB:TCF)
:TCF
TCF Stock Chart & Stats
Day’s Range― - ―
52-Week Range0.20p - 1.25p
Previous CloseN/A
Volume87.69K
Average Volume (3M)1.37M
Market Cap
£5.05M
Enterprise ValueN/A
Total Cash (Recent Filing)£2.00M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Jun 11, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,148,963,600
10 Day Avg. Volume1,881,138
30 Day Avg. Volume1,374,495
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Evgen Pharma News
PremiumCompany Announcements
Theracryf PLC Sees Change in Shareholder Structure
PremiumCompany Announcements
TheraCryf Partners with Pharmaron to Advance Orexin-1 Addiction Programme
PremiumCompany Announcements
TheraCryf Announces Board Appointment and Strategic Incentive Plan
PremiumCompany Announcements
TheraCryf Announces Investor Webinar to Discuss Key Drug Development Programs
PremiumCompany Announcements
Theracryf PLC Announces Major Holdings Change
PremiumCompany Announcements
Theracryf PLC Announces Change in Major Shareholder HoldingsPremiumCompany Announcements
TheraCryf Plc Announces Major Change in Voting Rights
PremiumCompany Announcements
Theracryf PLC Announces Change in Voting Rights Structure---
Options Prices
Currently, No data available
---
Ownership Overview
1.83% Insiders
―
Mutual Funds
― Other Institutional Investors
98.17% Public Companies and
Individual Investors
TCF FAQ
What was Evgen Pharma’s price range in the past 12 months?
Evgen Pharma lowest share price was 0.20p and its highest was 1.25p in the past 12 months.
What is Evgen Pharma’s market cap?
Evgen Pharma’s market cap is £5.05M.
When is Evgen Pharma’s upcoming earnings report date?
Evgen Pharma’s upcoming earnings report date is Jun 11, 2025 which is in 21 days.
How were Evgen Pharma’s earnings last quarter?
Evgen Pharma released its earnings results on Nov 28, 2024. The company reported -0.003p earnings per share for the quarter, missing the consensus estimate of N/A by -0.003p.
Is Evgen Pharma overvalued?
According to Wall Street analysts Evgen Pharma’s price is currently Overvalued.
Does Evgen Pharma pay dividends?
Evgen Pharma does not currently pay dividends.
What is Evgen Pharma’s EPS estimate?
Evgen Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evgen Pharma have?
Evgen Pharma has 2,148,963,600 shares outstanding.
What happened to Evgen Pharma’s price movement after its last earnings report?
Evgen Pharma reported an EPS of -0.003p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.818%.
Which hedge fund is a major shareholder of Evgen Pharma?
Currently, no hedge funds are holding shares in GB:TCF
---
Company Description
Evgen Pharma
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company's lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase I clinical trials for the treatment of neurodevelopmental disorders and glioblastoma, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addiction and anxiety; and atypical dopamine transporter inhibitor (DAT), which is in late preclinical stage targeting fatigue and narcolepsy. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
---
Technical Analysis
Oxford BioDynamics
―
Cizzle Biotechnology Holdings PLC
―
HemoGenyx Pharmaceuticals Plc
―
Fusion Antibodies Plc
―
Aptamer Group Plc
―
---